Broadview Ventures Promotes David Prim, PhD to Principal. Broadview Ventures, a mission-driven investment organization dedicated to accelerating the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke, today announcesthe promotion of David Prim, PhD, to Principal. Since joining Broadview Ventures as a Senior Associate in 2021, David has sourced, evaluated, and closed several key medical device investments, and has partnered closely with existing portfolio companies to help guide their operational and corporate development. David currently serves on the boards of CorFlow Therapeutics, Puzzle Medical Devices, and Vascular Graft Solutions. In the Principal role, David will continue to expand his responsibility in sourcing new opportunities, leading scientific, clinical, and corporate due diligence efforts, structuring transactions, and managing portfolio company investments. Broadview is committed to the career progression and recognition of its investment team members. Over the last three and a half years, David has demonstrated the ability to identify high-potential founders, execute investment due diligence, lead and syndicate investments, and promote the success of management teams. We are pleased to formally recognize David’s talent and accomplishments with his promotion to Principal. We look forward to continued partnership with David in this new role. Congratulations David Prim, PhD 👏
Broadview Ventures Inc
Venture Capital and Private Equity Principals
Boston, MA 1,122 followers
Broadview Ventures is a mission-driven, cardiovascular health-focused investment organization.
About us
Broadview Ventures is a mission-driven investment organization. Its primary investment goal is to improve human health in the areas of cardiovascular disease and stroke. We define success as improving human health by bringing innovative technologies to patients.
- Website
-
http://broadviewventures.org
External link for Broadview Ventures Inc
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2009
Locations
-
Primary
Get directions
265 Franklin Street
Suite 1902
Boston, MA 02110, US
Employees at Broadview Ventures Inc
Updates
-
We’re thrilled that XII Medical closed its Series B financing to continue advancing the company's truly novel neuromodulation therapy to treat obstructive sleep apnea. Broadview co-led XII's Series A financing and we're excited to continue our support through an investment by Longview Ventures.
We welcome our lead investor Omega Funds and new investor Intuitive Ventures, and are grateful to our existing investors including founding investor Cleveland Clinic Innovations, Ajax Health, Broadview Ventures Inc, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, CincyTech and our unnamed strategic investor. Saoussen Ben Halima, PhD Claudio Nessi Marla Jalbut, MD, MBA Murielle Thinard McLane Jotthe Kannappan Vijay Rajasekhar, MD, MBA Vivian Emmely Golfin, MD JD Friedland Zach Eisen Duke Rohlen Aftab Kherani Doug Koo Shane Kreidel Daniel Gottlieb Maria Berkman, MD Anthony Natale, M.D. Eric S. Tatyana Hower Steph Ison Samuel Lee, MD, MBA Ashley Keating Anthony Caparso John Sam Bhavesh Patel Rabih Nassif Andrew Wu
-
Broadview Ventures Inc reposted this
Congrats to Garrett Schwab Anthony Caparso Anthony Natale, M.D. and the entire team at XII Medical! So excited to continue supporting the company!
We welcome our lead investor Omega Funds and new investor Intuitive Ventures, and are grateful to our existing investors including founding investor Cleveland Clinic Innovations, Ajax Health, Broadview Ventures Inc, Longview Ventures, Aperture Venture Partners, JobsOhio Growth Capital Fund, CincyTech and our unnamed strategic investor. Saoussen Ben Halima, PhD Claudio Nessi Marla Jalbut, MD, MBA Murielle Thinard McLane Jotthe Kannappan Vijay Rajasekhar, MD, MBA Vivian Emmely Golfin, MD JD Friedland Zach Eisen Duke Rohlen Aftab Kherani Doug Koo Shane Kreidel Daniel Gottlieb Maria Berkman, MD Anthony Natale, M.D. Eric S. Tatyana Hower Steph Ison Samuel Lee, MD, MBA Ashley Keating Anthony Caparso John Sam Bhavesh Patel Rabih Nassif Andrew Wu
XII MEDICAL RAISES $45 MILLION IN SERIES B FINANCING TO ADVANCE BEST-IN-CLASS NEUROMODULATION THERAPY FOR OBSTRUCTIVE SLEEP APNEA
prnewswire.com
-
Congratulations to Lucy O'Keeffe and the entire team at CroiValve for closing the Series B financing! Broadview has been an investor since 2019 and we're excited to continue supporting the company and the TANDEM II US EFS!
CroíValve raises $16 Million in Series B financing to fund the TANDEM II US Early Feasibility Study of the DUO System for patients with severe or greater symptomatic tricuspid regurgitation. https://lnkd.in/gr9-6umF The DUO System is a novel transcatheter heart valve that works in tandem with the native tricuspid valve to restore valve function while leaving the patient’s right heart and native valve apparatus untouched through an innovative anchoring mechanism. Designed to treat a broad patient population, the DUO System accommodates the heterogeneity of patient anatomies while avoiding contact with critical structures in the right heart. #CroiValve#DUO System Learn more about the DUO System: https://croivalve.com CroíValve is a clinical stage medical device company focused the development of a novel transcatheter device for the treatment of tricuspid regurgitation, with R&D & Operations activities based in Ireland and Clinical & Regulatory based in the U.S. Caution: The DUO System is an investigational device and not for sale in any geography.
-
-
Congratulations to Samir Ounzain Daniel Blessing and the entire HAYA Therapeutics team on winning the inaugural Andreas & Thomas Strüngmann Award! This recognizes the organization's diligent work to advance genetic medicines targeting noncoding RNA for the treatment of complex, chronic diseases. Broadview Ventures Inc is a proud supporter of this pioneering work and we look forward to realizing the potential of the Company’s novel therapeutics in heart failure and beyond.
HAYA's co-founders, CEO Samir Ounzain, Ph.D., and CTO Daniel Blessing, Ph.D., were deeply honored to receive the inaugural Andreas & Thomas Strüngmann Award on Friday night during the "Festival of the Future" in Munich. The new award, which recognizes life science entrepreneurs developing revolutionary technologies in the DACH region (Germany, Austria, and Switzerland), is named for twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who were formative in the establishment of BioNTech, a pioneer in mRNA vaccines. The HAYA team is incredibly proud of Samir and Daniel for this incredible achievement. Their entrepreneurial spirit, passion and vision have been instrumental in propelling HAYA forward, fostering growth through our groundbreaking regulatory genome platform and strong product pipeline. Vielen, vielen dank to ATHOS and the 2024 jury members, and congratulations to all of this year's finalists! For more about the award, please read the full release: https://lnkd.in/gBC7nyFm #lifesciences #biotech #entrepreneurship
-
-
Broadview Ventures Inc reposted this
HAYA's co-founders, CEO Samir Ounzain, Ph.D., and CTO Daniel Blessing, Ph.D., were deeply honored to receive the inaugural Andreas & Thomas Strüngmann Award on Friday night during the "Festival of the Future" in Munich. The new award, which recognizes life science entrepreneurs developing revolutionary technologies in the DACH region (Germany, Austria, and Switzerland), is named for twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who were formative in the establishment of BioNTech, a pioneer in mRNA vaccines. The HAYA team is incredibly proud of Samir and Daniel for this incredible achievement. Their entrepreneurial spirit, passion and vision have been instrumental in propelling HAYA forward, fostering growth through our groundbreaking regulatory genome platform and strong product pipeline. Vielen, vielen dank to ATHOS and the 2024 jury members, and congratulations to all of this year's finalists! For more about the award, please read the full release: https://lnkd.in/gBC7nyFm #lifesciences #biotech #entrepreneurship
-
-
Congratulations to the team at AtaCor Medical, Inc. for closing its $28 million Series C financing! Broadview is excited to continue our support of AtaCor through an investment by Longview Ventures. Arboretum Ventures, Hatteras Venture Partners, Catalyst Health Ventures, BayMed Venture Partners, Rick Sanghera https://lnkd.in/evfGB3Kq
We are excited to announce that we have successfully closed $28M in our Series C financing round. Funding from this round will support regulatory submissions for our temporary pacing platform and the pilot study for our third generation EV-ICD lead system. Congrats to the entire AtaCor team on this important milestone! Read the full announcement here (https://lnkd.in/gBP7ji6j). #atacor #cardiology #CRM @HRS #EV-ICD
-
-
IsomAb Appoints Dr Anker Lundemose as a Non-Executive Director https://lnkd.in/e9ea4YCM
IsomAb Appoints Dr Anker Lundemose as a Non-Executive Director
isomab.bio
-
Broadview is pleased to report another robust year of activities in 2023, with substantial progress made by our portfolio companies. #cardiovascularhealth
-
Broadview is excited to be supporting Isomab Ltd in its efforts to treat Peripheral Artery Disease. #peripheralarterydisease
IsomAb Announces Close of £7.5 Million Financing to Accelerate Lead Candidate for Treatment of Peripheral Arterial Disease Seed Financing was led by Broadview Ventures
obn.org.uk